Navigation Links
Greater certainty in monitoring 3 therapeutic medications is facilitated by new CRMs
Date:11/18/2009

Rockville, Md., November 18, 2009 To help bring greater certainty to the measurement of medication levels in a patient's bloodstream for three drugs with narrow therapeutic ranges, the U.S. Pharmacopeial Convention (USP) is releasing new certified reference materials (CRMs).

The three new CRMs are for carbamazepine, an anticonvulsant and mood stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder; phenytoin, commonly used as an antiepileptic; and theophylline, used in the treatment of respiratory diseases. These three drugs are among a group of medicines that are often monitored in the bloodstream of patients that have been prescribed the drugs. Such medicines may need to be carefully monitored for a number of reasons, including a narrow therapeutic range or risk of toxicity. Therapeutic drug monitoring may also be necessary for drugs that are intended to maintain the absence (as opposed to the presence) of a medical condition, such as seizures.

CRMs represent an important step forward for USP reference standards, which are the physical materials used to demonstrate compliance to written USP standards designating a medicine and its ingredients' identity, quality, purity, strength and consistency. CRMs are reference standards accompanied by a certificate of analysis. A CRM is rigorously tested for one or more chemical or physical properties (such as purity). A property value with associated uncertainties certified to be true based on these tests is assigned to the CRM after a thorough statistical treatment of the data. The path of metrological traceability, which provides information on how the measurement was made and which standards were used to support the measurement, is included in the Certificate of Analysis, as well as the estimated level of uncertainty associated with the assigned value. This added information regarding uncertainties and traceability is provided for users of the reference materials. Procedures for determining compliance with USP compendial quality standards remain unchanged since, as stated on the Certificates of Analysis, the associated uncertainties are not used as part of the calculation value for quantitative USPNF applications.

The new CRMs will be used by the in vitro diagnostic device industry, which manufactures medical devices that examine specimens derived from the human body (e.g., blood or tissue donations) to provide information related to a physiological or pathological state or to monitor therapeutic measures. Requirements in Europe state that all measurements should be traceable to standards of a "higher metrological order," that is, more certain measurements. The International Organization for Standardization (ISO) states that, where possible, such standards should be CRMs. USP is the first global pharmacopeia to be ISO-certified as a producer of chemical CRMs.

"In releasing these three new CRMs, USP is meeting the needs of the multi-national in vitro diagnostic device industry," said William Koch, Ph.D., USP's chief metrology officer. "For these three products, a higher degree of certainty in measurement is extremely important. In Europe specifically, regulations support use of CRMs for in vitro diagnostic devices. However, this is useful for manufacturers of these medicines worldwide."


'/>"/>

Contact: Francine Pierson
fp@usp.org
301-816-8588
US Pharmacopeia
Source:Eurekalert

Related medicine news :

1. Older People at Greater Risk of Swine Flu Death
2. Visiting Nurse Association of Greater Philadelphia and Philadelphia Fire DepartmentAwarded by National Fire Protection Association
3. Women Are at Greater Risk Than Men of Graft Loss After Undergoing Liver Transplantation for Hepatitis C-related Liver Disease
4. New Census Reveals Decline in Greater Los Angeles Homelessness
5. Blacks at Greater Risk for Colorectal Cancer
6. YWCA Greater Los Angeles Presents Black & White Benefactrix Ball
7. New data showed type 2 diabetes patients experienced greater blood sugar reductions
8. Increased levels of Muellerian-inhibiting substance could mean greater breast cancer risk
9. Empire BlueCross BlueShield Launches Art Heals Program with Museum for African Art, Greater New York Hospital Association
10. Largest Survey of Its Kind Finds the Psychological and Social Effects of Psoriasis Greater for Women
11. Sexual Satisfaction May Lead to Greater Well-Being in Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... Healthcare companies are trying to ... rapidly reject an outdated healthcare executive resume. , “If you’re a healthcare executive open ... resume and wondering if it’s as ready as you are for a new job ...
(Date:4/27/2017)... (PRWEB) , ... April 27, 2017 , ... ... named the 2017 North American CAREGiverSM of the Year for her extraordinary compassion ... one of its 60,000 North American professional caregivers for the prestigious award each ...
(Date:4/27/2017)... ... 27, 2017 , ... Offering the purest product of its kind, Swissx Labs ... more potent than the market has seen before. Swissx uses proprietary strains of hemp ... patented chromatography process for extraction, to produce its CBD oil--maximizing its benefits for health ...
(Date:4/26/2017)... ... April 26, 2017 , ... Jump Technologies, Inc., ... announced it has completed a round of funding to accelerate its growth strategies. ... Black Granite Capital is a growth equity firm focused on investments in healthcare ...
(Date:4/26/2017)... , ... April 26, 2017 ... ... is thrilled to announce the ATA 2017 President’s Awards recipients, comprised of ... demonstrated superior healthcare delivery. , The ATA 2017 President’s Awards recognize ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... today announced that it will be participating in the ... the InterContinental Hotel in Boston, Massachusetts ... present at 11:20 a.m. Eastern Time. A ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  ...
(Date:4/20/2017)... 2017   ZappRx, Inc ., a digital health company ... today announced it closed $25 million in Series B funding ... based in Seattle that is part ... The Series B round included participation from SR One ... GV (formerly Google Ventures). As part of the ...
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Manufacturing Services Market Analysis By Service (Manufacturing, Research), By Country, ... - 2025" report to their offering. ... The Latin American pharmaceutical contract manufacturing ... 2025 Low drug registration cost in Latin American ...
Breaking Medicine Technology: